Pregabalin versus gabapentin in the treatment of sciatica:  study protocol for a randomised, double-blind, cross-over trial (PAGPROS) by Robertson, Kelvin et al.
STUDY PROTOCOL Open Access
Pregabalin versus gabapentin in the
treatment of sciatica: study protocol for a
randomised, double-blind, cross-over trial
(PAGPROS)
Kelvin Robertson1,2*, Laurence A. G. Marshman2,3, Maria Hennessy4, Linton Harriss5 and David Plummer6
Abstract
Background: There is currently an absence of high-grade evidence regarding the treatment of chronic sciatica (CS).
Whilst gabapentin (GBP) and pregabalin (PGB) are both currently used to treat CS, equipoise exists regarding their
individual use. In particular, no head-to-head study of GBP and PGB in CS exists. Despite equipoise, most countries’
formulary regulatory authorities typically favour one drug for subsidy over the other. This hinders interchange
wherever the favoured drug is either ineffective or not tolerated. The primary aim of this study is to conduct a
head-to-head comparison of the efficacy of PGB versus GBP for CS based on outcomes on a visual analogue scale
(VAS) and the Oswestry Disability Index (ODI).
Methods/design: We are conducting a prospective, randomised, double-blind, double-dummy cross-over study.
Included patients will be over 18 years old and have unilateral CS with radiological confirmation of corresponding
neural compression/irritation. Pregnant women, those with major organ disease, or those with creatinine clearance
< 60 ml/minute will be excluded. Patients will continue their current pain medication at study onset, conditional
upon dosage consistency during the prior 30 days. Each drug will be titrated up to a target dose (GBP 400–800 mg
three times daily, PGB 150–300 mg twice daily) and taken for 8 weeks. The first drug will then be ceased; however,
cross-over will be deferred pending a 1-week washout period. Drug efficacy will be assessed using the VAS and ODI.
Results of the Health Locus of Control Scale and side effect frequency/severity will be used to determine psychological
functioning. Assuming the hypothesis that PGB will display a superior effect, the sample size required is n = 38 with 80%
power and a 5% type I error rate. Results will be analysed via intention-to-treat methodology.
Discussion: This study will establish the efficacy of PGB compared with GBP in reducing pain in people with sciatica and
lead to greater understanding of the treatment options available.
Trial registration: Australian and New Zealand Clinical Trials Registry, 12613000559718. Registered on 17 May 2013.
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Background
Sciatica or sciatic neuralgia, a common form of lumbosa-
cral radiculopathy, is characterised by low back pain which
radiates to the leg and which may be accompanied by sen-
sory loss, motor weakness and/or reflex abnormalities.
Sciatica is a symptom defined as well-localised leg pain
with a sharp, shooting or burning quality that approxi-
mates to the dermatomal distribution of the sciatic nerve
down the posterior lateral aspect of the leg [1]. It is often
associated with numbness or paraesthesia in the same
distribution but typically extends beyond the limits of
perceived pain in either a dermatomal or sclerotomal ana-
tomical fashion [2, 3]. The term sciatica is used by clini-
cians in different ways: Some refer to any leg pain referred
from the back as sciatica; others prefer to restrict the term
to pain originating from the lumbar nerve root. Others be-
lieve sciatica is a form of ‘neuropathic’ pain caused by
compression or irritation of the roots or nerves that com-
prise the sciatic nerve [1, 4]. Chronic sciatica (CS) is sciat-
ica which has been present for more than 3 months
despite active conservative management, including phys-
ical therapy. CS may complicate previous chronic low
back pain; however, it may also present purely as an
isolated phenomenon [1, 4].
The annual prevalence of sciatica varies widely (1.6–
43%) with male predominance [4]. Sciatica accounts for
5% of patients with low back pain presenting to primary
care practices and 30% have persistent pain for longer
than 12 months. Of these 30% presenting to primary
care, 20% are already out of work, and 5–15% require
surgery. Over half of patients with sciatica will have pain
4 years post-diagnosis, and the socio-economic cost per
country per year is estimated to be $128 million for in-
hospital care, $730 million for absenteeism and $708
million for disability [5].
Anti-depressants such as tricyclic anti-depressants
(TCAs; e.g., amitriptyline) are widely used to treat neuro-
pathic pain (NP), including CS, as first-line therapy after
failure of simple analgesics. On the basis of ‘moderate-
quality’ evidence, The National Institute for Health and
Care Excellence – United Kingdom (NICE-UK) reported
TCA efficacy over placebo for NP [6]; however, on the
basis of ‘high-quality’ evidence, TCAs were also signifi-
cantly more likely than placebo to produce side effects
(SEs). Extrapolating NICE-UK guidelines, prescribing au-
thorities (e.g., Australian Therapeutic Guidelines [ATG])
often insist on trialling TCAs first for NP prior to introdu-
cing second-line agents. Limited information, however, is
available regarding TCA use in CS. In one rare cross-over
study, nortriptyline—alone or combined with morphi-
ne—had no significant benefit over placebo [6].
Anti-convulsant anti-neuropathic agents such as gaba-
pentin (GBP) and pregabalin (PGB) are also widely used
to treat NP, including CS. On the basis of ‘moderate- to
high-quality’ evidence, NICE-UK noted the efficacy of
these agents over placebo for NP [6]. Australian pre-
scribing authorities (e.g., ATG) recommend anti-
neuropathic agents as second-line agents for NP, even
though NICE-UK did not actually favour TCAs over
anti-neuropathics as first-line agents (or vice versa).
However, NICE-UK states that when introducing
second-line agents, ‘overlap’ with pre-existent regimens
should be considered to avoid decreased pain control
[6]. A recent literature review provides information on
the individual efficacy of PGB and GBP over placebo for
CS; however, when compared head-to-head, no firm
conclusions can be made [7].
In summary, sciatica, like most NP states, often proves
resistant to simple analgesic regimens (including para-
cetamol, non-steroidal anti-inflammatory drugs
[NSAIDs] or opioids) and recommended first-line TCAs
[1, 4]. Instead, the drugs most commonly used currently
in both CS and NP are GBP or PGB [1, 4]. PGB and
GBP are both analogues of γ-aminobutyric acid, a sub-
stance known to modulate calcium channel subunits.
Both GBP and PGB may therefore possibly act by de-
creasing neurotransmitter release associated with central
sensitisation in both CS and NP.
As with NP, there is currently an absence of high-
grade evidence regarding the medical treatment of CS
[1, 6]. No adequately powered direct ‘head-to-head’ trials
comparing either PGB or GBP with other drugs are
extant [1, 6]. Indirect comparisons, using placebo as the
common comparator, have been published; however,
each has represented differing patient populations, dif-
fering primary outcomes and differing pain measure-
ment scales [6]. Authors of a recent review concluded,
albeit based on weak evidence, that efficacy and SEs with
GBP and PGB were probably similar [7].
Notwithstanding this information, citing minor titra-
tion but definite cost advantages, NICE-UK nevertheless
favoured PGB over GBP [6]. However, costs of either
PGB or GBP vary widely globally. Moreover, costs vary
unpredictably (i.e., PGB more expensive than GBP or
vice versa) on a global basis [7]. Despite this, formulary
regulatory authorities in most countries have, like NICE-
UK, favoured one drug over the other. Furthermore, and
somewhat paradoxically, formulary regulatory authorities
in most countries have typically favoured the more
expensive drug, whether GBP or PGB [7]. For example,
GBP is currently available on the Australian Pharma-
ceutical Benefits Scheme (PBS) in Australia and some
hospitals in the United Kingdom only for epilepsy; it is
not listed for NP. PGB, by contrast, is subsidised on the
PBS for NP. The U.S. Food and Drug Administration,
along with Health Canada, have adopted reimbursement
criteria similar to that of the Australian PBS; notwith-
standing this, both GBP and PGB can be accessed in the
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United States and Canada via special access schemes (if
patients satisfy stringent criteria for NP). In marked
contrast, GBP is listed for use in treating both partial
seizures and NP throughout Europe. The rulings of for-
mulary regulators have therefore been inconsistent and
dependent upon the individual body. Such action
hinders interchange wherever the favoured drug is either
ineffective or not tolerated [7]. Given that no evidence
supports unhindered PGB-GBP interchange and that no
study has directly challenged GBP and PGB head-to-
head, neither GBP nor PGB should probably be
favoured, given current evidence [7].
Prospective ‘head-to-head’ studies are therefore urgently
required to provide a robust evidence base for GBP or
PGB use in sciatica [4]. Both medications have previously
displayed efficacy when compared with placebo [1, 8, 9].
We therefore aimed to perform the first study to assess
GBP and PGB directly head-to-head for treatment of CS.
Objectives
Primary objective and outcome
Our primary objective is to demonstrate if either GBP or
PGB demonstrates superiority over the other in terms of
efficacy for the treatment of patients diagnosed with CS.
The co-primary outcome is leg pain intensity using a vis-
ual analogue scale (VAS) measured at baseline and at
weeks 4, 8, 10, 14 and 18. The participants will be asked
to rate their average leg pain over the last 24 h on a
scale of 10, with zero representing ‘no leg pain’ and 10
representing the ‘worst pain imaginable’ [10].
The co-primary outcome is the Oswestry Disability
Index (ODI) [10], measured at baseline and at weeks 4,
8, 10, 14 and 18, to assess disability. The Health Locus
of Control Scale (HLOC) will also be used at baseline
and at weeks 4, 8, 10, 14 and 18 to assess participants’
decision-making processes because we have identified
compliance with these medications as being low [10].
Secondary objective and outcome
Our secondary objective is to demonstrate if one drug
(i.e., either GBP or PGB) demonstrates superiority over
the other in terms of the frequency and severity of SEs
in the treatment of sciatica. The key secondary outcome
will be the record of frequency and severity of SEs. De-
tails of SEs will be collected at weeks 4, 8, 10, 14 and 18.
The most common SEs of PGB are dizziness and som-
nolence [11]. The most common SEs of these medica-
tions are dizziness (27%), drowsiness (22%) and
decreased memory (20%) [10].
Methods/design
The Pregabalin and Gabapentin Prospective Clinical
Trial for the Treatment of Sciatica: A Randomised,
Double-Blind, Cross-over Study (PAGPROS) is a
double-blind, randomised, double-dummy, cross-over
trial comparing PGB with GBP for the treatment of CS
(Fig. 1). Ethics approval was obtained from the local hu-
man research ethics committee, and the study has been
registered with the Australian and New Zealand Clinical
Trials Registry (ANZCTR, 12613000559718). The study
protocol follows the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) statement
[12] (Additional file 1), and a SPIRIT figure and CON-
SORT diagram are provided in Figs. 1 and 2.
Participants and recruitment
Participants with unilateral CS will be recruited from at-
tendance at a specialist neurosurgery clinic in a large ter-
tiary hospital located in Townsville, Australia. The study
specialists, comprising consultant neurosurgeons, will
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Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure for Pregabalin and Gabapentin Prospective Clinical Trial
for the Treatment of Sciatica: A Randomised, Double-Blind, Cross-over Study (PAGPROS). HLOC Health Locus of Control Scale
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perform a medical evaluation to gain relevant medical and
medication history and screen the patient against the eligi-
bility criteria. This initial intervention will include baseline
scores for VAS, ODI and HLOC. The patient will then be
directed to the trial pharmacist, who will remain inde-
pendent of the treating team, for consent and signature of
the informed consent document.
Patients are deemed eligible if they meet all of the
following criteria:
 Pain radiating into one leg only to, at or below knee
level
 Magnetic resonance imaging/computed
tomography-confirmed sciatica caused by a
degenerative condition (e.g., degenerative disc
disease, bone spur growth, degenerative scoliosis)
 Naive to PGB and GBP use
 Aged 18 years or older
 Sufficient understanding of the English language
or interpretation assistance available to complete
the study treatment and assessments
Concomitant medication, including analgesics and central
nervous system CNS depressants (paracetamol, NSAIDs,
and opioids), can be continued as long as the medication
dose has been stable for 30 days prior to the start of the
study.
Patients will be excluded if they meet any of the
following criteria:
 Pregnant or breastfeeding women or females
planning conception during the study period
 Patient history or laboratory results that suggest the
presence of inherited neuropathy or neuropathy
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram for Pregabalin and Gabapentin Prospective Clinical Trial for the Treatment
of Sciatica: A Randomised, Double-Blind, Cross-over Study (PAGPROS)
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attributable to other causes (hypothyroidism,
vitamin B12 deficiency, connective tissue disease,
amyloidosis, toxic exposure)
 Major organ system disease, diabetic cardiovascular
autonomic neuropathy with abnormality in
sympathovagal balance, baseline postural
hypotension of more than 20 mmHg
 Specific contraindications to PGB or GBP (allergy to
or significant renal impairment); PGB and GBP are
both predominantly renally excreted, so patients
with an estimated creatinine clearance < 60 ml/
minute will be excluded
 Other neurologic medications such as serotonin
reuptake inhibitors (paroxetine, fluoxetine), dual
(serotonin and noradrenaline) reuptake inhibitors
(venlafaxine), benzodiazepines, anti-convulsant
medications (valproic acid, carbamazepine), anti--
psychotic medications (clozapine, olanzapine, risper-
idone) or bipolar disorder medications (lithium)
 People with a diagnosis of cancer, dementia, severe
mental illness or other condition which will
significantly reduce the ability to consent and/or
fully undertake the program
 Diabetic and/or HIV-related neuropathies
If a patient is eligible, the unblinded independent trial
pharmacist will gain informed consent and notify the re-
search team. The participant will then be randomised,
and the pharmacist will dispense and counsel on the
study medications and arrange visit appointments with
reminders. At this point, baseline data will be confirmed
by the pharmacist as collected at the first visit, or subse-
quently via telephone, before the participant commences
the study medication. Following baseline data collection,
the researcher will instruct the participant to break the
seal on the medication pack and commence the study
medicine as per the dosage instructions. At this point,
the participant is considered to have been included in
the study.
To ensure consistency, the study researchers will en-
sure that the protocol is being followed and that good
clinical practice is being monitored. General practi-
tioners will be able to refer community patients into the
trial via a trial specialist hotline contact number whereby
the patient is screened by a study specialist to ensure
consistency of enrolment.
Randomisation and blinding
The trial pharmacist (un-blinded) will generate a ran-
domisation code using a computer-derived permuted
block with varying block size sequence. Manufacturing
and preparation of the medication capsules will be
performed by an external good manufacturing practice-
accredited facility. The unblinded pharmacist will be
involved in the preparation of the medication kits as per
the randomisation schedule. The sequence will follow a
2 × 2 sequential design whereby participants will receive
PGB first, then GBP (or vice versa), in a double-blinded
fashion. Owing to the variability in regular dosage fre-
quency between the medications (PGB twice daily, GBP
thrice daily), study medication packs will contain three
bottles each, correlating to the dosage times of morning,
lunchtime and night, so as to maintain blinding. Medica-
tion packs pertaining to the PGB arm will have placebo
incorporated as the lunchtime dose with all medications
being indistinguishable. The randomisation schedule will
remain concealed from other researchers. Placebo cap-
sules will have an appearance identical to the active cap-
sules. The randomisation process will ensure concealed
allocation and blinding of the specialist, the participant
and the outcome assessor.
Study treatment
Participants will be randomised to commence treatment
on either PGB or GBP. As a result of the cross-over
methodology, participants will have the opportunity to
experience both PGB and GBP, and we predict little or
no carry-over effects (medium- or long-term) after the
washout period. We believe the incorporation of a
stand-alone placebo arm is unethical in trials where par-
ticipants with moderate to severe pain are recruited.
The starting dose of PGB is 150 mg once daily for the
first week. This will be titrated to the participant’s opti-
mal dose up to a maximum of 300 mg twice daily, de-
pending on their progress and tolerance at each dose
level. The starting dose for GBP is 400 mg once daily for
the first week. This will be titrated to the participant’s
optimal dose up to a maximum of 800 mg thrice daily,
depending on their progress and tolerance at each dose
level. These doses are based on national recommenda-
tions from the Australian Medicines Handbook [11]. In
the standard study dosing regimen (Table 1), we expect
a 4-week titration period, after which the maximum tol-
erated dose for each participant will be maintained for
4 weeks before the first study medication is ceased in
preparing for washout. The washout period between
treatment phases will last 1 week, which is sufficient for
these medications because they possess a short half-life
(5–7 h). The dosage of either PGB or GBP can be
amended at any stage in PAGPROS on the basis of effi-
cacy and/or SEs by communication between the study
specialist and the study pharmacist. The maximum
treatment period is 8 weeks [13].
The titration and dosage regimen are based on recom-
mendations from clinical practice and medication guide-
lines such as the Australian Medicines Handbook and
product prescribing information. Both medications have
the potential for adverse neurological SEs, and hence a
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slow ascent in dose will contribute to mitigating this risk
for participants and increasing compliance with the trial
protocol. Simultaneously prior to washout, the dosage
will be gradually reduced instead of being abruptly
halted, further decreasing the likelihood of medication
misadventures for the participants (and increasing
compliance).
In addition to PGB or GBP, participants may continue
concomitant medications (including analgesics) as long as
the dosage has been stable for 30 days prior to commen-
cing the study period. These concomitant medications will
be closely monitored and recorded in the case report form
(CRF). Medicines for NP include anti-depressants, select-
ive serotonin and noradrenaline reuptake inhibitors, top-
ical lignocaine and other anti-convulsant medications
[14]. Note that this practice is entirely consistent with
NICE-UK guidelines, which state that when super-adding
second-line agents for analgesic control (such as GBP and
PGB), ‘overlap with first-line agents is encouraged to avoid
decreased pain-control’. To our knowledge, only one pro-
spective cohort study has reflected this practice with GBP
in CS [14]. However, participants should not take con-
comitant medication that could result in an adverse inter-
action with PGB or GBP, including medicines that might
increase the risk of excessive sedation (for example, ben-
zodiazepines) [11]. No other pain interventions will be
permitted throughout the study period; if considered
necessary, then such patients will be withdrawn from
PAGPROS.
Participating in PAGPROS is completely voluntary,
and participants can stop taking part at any time without
explanation or prejudice. Ceasing to participate in PAG-
PROS may be considered, for example, wherever partici-
pants wish to explore the possibility of other treatments,
including other medications or interventions (see above).
In some cases, participants may find that the starting
dose of either PGB or GBP, whilst efficacious, produces
unwanted SEs [10]. In such cases, a lower dose may be
required, at least for a period of time. Because this can-
not be accommodated within the current PAGPROS
protocol, such patients will be removed from the study,
and their data will be analysed as per intention-to-treat
(ITT) principles; however, they may still form part of a
prospective cohort for parallel study.
Data collection
Data collection will be conducted by the study researchers
via telephone, email or online at baseline (before medica-
tion commencement) and at weeks 4, 8, 10, 14 and 18.
Week 10 data collection will act as the cross-over second-
ary baseline for analysis purposes. Data will be entered
into CRFs by dedicated trained staff. Each participant will
receive up to seven face-to-face or telephone consultations
with the trial pharmacist to commence treatment, moni-
tor progress and adjust the dose of the study medication
over the 8-week treatment periods. These visits will also
incorporate a medical evaluation and collection of primary
and secondary outcomes. Participants will receive usual
neurosurgical care independent of and parallel to
PAGPROS.
The use of prior and continued analgesic medicines
will be collected at baseline. Adherence to study medica-
tion will be documented through a self-reported daily
medication diary and by counting the returned medicine
compared with the prescribed regimen as recorded by
the trial pharmacist. Participants will be asked to return
used and unused study medications at each visit.
Data integrity and analysis
The integrity of trial data will be monitored by regularly
scrutinising data files for omissions and errors. We will
perform double data entry of the primary and key sec-
ondary outcomes. The source of any inconsistencies will
be explored and resolved. Electronic data will be stored
on a secure server, and paper copies will be locked in a
cabinet. Data will be accessible only by researchers, and
participant confidentiality will be maintained through se-
cure password-protected data storage during and after
PAGPROS.
Data will be de-identified prior to statistical analysis,
which will be performed on an ITT basis. Normality of
data distribution will be assessed, and appropriate
Table 1 PAGPROS medication titration schedule
Medication Total daily dose
Week Pregabalin
1 1 × 150-mg capsule in the morning 150 mg/day
2 1 × 150-mg capsule three times daily (middle dose is placebo) 300 mg /day
3–8 2 × 150-mg capsules three times per day (middle dose is placebo) 600 mg/day
Week Gabapentin
1 1 × 400-mg capsule in the morning 400 mg/day
2 1 × 400-mg capsule three times per day 1200 mg/day
3–8 2 × 400-mg capsules three times per day 2400 mg/day
PAGPROS Pregabalin and Gabapentin Prospective Clinical Trial for the Treatment of Sciatica: A Randomised, Double-Blind, Cross-over Study
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parametric (Student’s t test or analysis of variance) or non-
parametric (Wilcoxon signed-rank test, Wilcoxon rank--
sum tests) tests for between-group differences will be per-
formed. Statistical significance will be assessed at p < 0.05.
Subgroup analysis may be implicated and considered as
PAGPROS develops. Time-to-event analysis will be under-
taken using Kaplan-Meier estimates on the week 8 and
week 18 VAS scores. Missing data will be handled by a sin-
gle imputation method whereby the last observation will
be carried forward and used as a surrogate for the missing
value. This method is the favoured approach for replacing
missing data because it is conservative, yields an appropri-
ate estimate of variation in outcome and is unlikely to bias
towards the alternative hypothesis [15]. An alternative ap-
proach to missing data may be use of a longitudinal
mixed-effects model incorporated into the analyses.
Sample size
We hypothesise that over an 8-week treatment period,
GBP will reduce pain on the VAS scale by an average of
4.5 points from (7.5 to 3.0) as per historical literature [16].
We predict PGB to show at least the same benefit. We hy-
pothesise that PGB will display superiority over GBP by at
least a 20% better relative reduction in VAS score, with a
resultant reduction of 5.4 (from 7.5 to 2.1) points from
baseline. This 20% relative reduction is based on the aver-
age reduction of pain symptoms compared with placebo
for indirect comparisons [1, 16]. Relative reduction will be
used because it is often more impressive and also to allow
for the instance of a lower-than-expected event rate,
which would lower the absolute risk reduction.
If the true difference in means of both arms of the
study is 0.9 with an SD of 1.2, in order to detect this
20% relative decrease in pain between GBP and PGB, we
will need to study 30 patients (15 per treatment arm) to
reject the null hypothesis with 80% power. The type I
error probability associated with this test of the null is
0.05. Assuming a 20% drop-out rate, the total sample
size will be 38 patients (19 per treatment arm). We have
chosen this large effect size and conservative SD on the
basis of anecdotal and specialists’ experience with this
cohort of patients. The benefits of the cross-over meth-
odology are evident with the small sample size required,
owing to each participant acting as his/her own control.
If this were a conventional parallel study design, the
sample size needed would be approximately 100 partici-
pants. We conservatively estimate that if two people can
be recruited per week, the study duration will be ap-
proximately 1.5 years.
Adverse experiences and monitoring
Potential risks of both PGB and GBP have been well
studied owing to their use for neuropathic conditions.
These risks have been minimised by our exclusion
criteria. Any SEs will be monitored weekly during
follow-up phone calls and examinations. Close monitor-
ing of other neurological pain medications will be done
with patient diaries. SEs were quantified in a latest meta-
analysis and given the rare SEs of both medications and
their likely effectiveness, and the potential benefits
outweigh the risks in this study [1].
During the recruitment period, a monitoring visit may
be applicable. The responsible monitor will be a special-
ist neurosurgeon who is not involved in the conduct of
the trial and is chair of the hospital patient safety com-
mittee. The purposes of monitoring are as follows:
 To ensure that the study is conducted according to
the protocol and applicable guidelines and
regulations
 To verify source data against data on the CRF and
in the database
 To check the security of stored data
 To confirm that the consent process, approved by
the Townsville Hospital Human Research Ethics
Committee, has been followed and to view a random
sample of original signed consent forms
 To review all serious adverse events (SAEs)
Interim data monitoring will take place in-house for
review of safety and SEs. The trial may be stopped if
more harm to patients is shown. The Pocock boundary
will be used as the stopping rule, whereby after each set
of 2n patient responses to a total of ‘K’ looks at the
data. "2n" patient responses means there will be at least
2 interim analyses whereby the stopping rule can be
enforced. This will be a group sequential approach
whereby the critical boundary (p < 0.018) will be set at
each look.
An adverse event is the appearance or worsening of
any undesirable sign, symptom or medical condition oc-
curring after starting the study, even if the event is not
considered to be related to the investigational drug. Any
SAE (defined as an event that is life-threatening or re-
sults in death, hospitalisation or significant disability)
will be reported immediately to the relevant authorities
(study monitor, ethics committee, data and safety moni-
toring board). If a potential relationship is suspected be-
tween the study drug and an SAE, then un-blinding to
treatment allocation is indicated, and the participant will
be withdrawn from PAGPROS.
Abnormal laboratory values or test results constitute
adverse events only if they induce clinical signs or symp-
toms, are considered clinically significant or require
therapy. The occurrence of adverse events should be
sought by non-directive questioning of the patient at
each visit during the study. Adverse events also may be
detected when they are volunteered by the patient
Robertson et al. Trials  (2018) 19:21 Page 7 of 10
during or between visits or through physical examina-
tions, laboratory tests or other assessments.
All adverse events will be recorded as follows:
 Severity grade: mild, moderate or severe
 Relationship to investigational drug: suspected/not
suspected
 Duration
 Continuation to an SAE
All adverse events will be treated appropriately. The
action taken to treat the adverse event should be
recorded. An SAE is defined as follows:
 Fatal or life-threatening
 Results in persistent or significant disability/
incapacity
 Constitutes a congenital anomaly/birth defect
 Requires inpatient hospitalisation or prolongation of
existing hospitalisation
To ensure patient safety, every SAE, regardless of sus-
pected causality, occurring after the patient has provided
informed consent and until 7 days after the patient has
stopped study participation will be noted by expedited
reporting to the Townsville Hospital and Health Service
Human Research Ethics Committee.
Modification of the protocol
Any modifications to the protocol that may impact the
design and conduct of the study will require a formal
protocol amendment. Such amendment will be agreed
upon by the study investigators and approved by the
local ethics committee prior to implementation. Once
approved, the changes will be communicated to the rele-
vant parties.
Discussion
The PAGPROS protocol presents the design and ration-
ale for a double-blind, double-dummy, randomised
cross-over trial comparing the efficacy of PGB with GBP
in treating CS. Owing to the variability in regular dosage
frequency between the medications (PGB twice daily,
GBP thrice daily), study medication packs will contain
three bottles each, correlating to the dosage times of
morning, lunchtime and night, to maintain blinding.
Medication packs pertaining to the PGB arm will have
placebo incorporated as the lunchtime dose, with all
medications being indistinguishable.
Thus, PAGPROS represents the first head-to-head
study to determine the relative role of either PGB or
GBP in the evidence-based medical management of CS.
However, in addition to efficacy, PAGPROS will also de-
termine the frequency and severity of SEs with PGB or
GBP. Thus, PAGPROS will determine the ‘efficacy versus
SE trade-off ’ with each drug and whether differences in
compliance rates result in consequences. For example, in
a prior study with GBP in treating CS, 31% of patients
ceased GBP within 1 week of treatment [10]. Moreover,
efficacy was significantly less in those who experienced
SEs in that study [10].
In PAGPROS, we will employ the HLOC to assess psy-
chological functioning with PGB or GBP in CS. In particu-
lar, PAGPROS will explore the prognosis of each drug
relating to questionnaire outcomes relating to patients’
insight into their psychological dysfunction. Thus, PAG-
PROS may determine deficits and provide information not
actually reported as SEs by the patients themselves. This
may prove to be an important aspect of the study. For ex-
ample, a prior prospective cohort study with GBP in treat-
ing CS revealed that, of 23 different SE types amongst 53%
of patients, more than half could have adversely affected
the ability to drive a motor vehicle safely or even to main-
tain employment [10].
Finally, the double-blind cross-over design of PAGPROS
may provide guidance regarding the implications of any
potential need to substitute one drug for the other. For
example, PAGPROS may determine whether SEs experi-
enced with one drug are also observed with the other (i.e.,
in the same patient, in close temporal succession after
cross-over). This may prove especially important should
PAGPROS demonstrate a between-groups null effect
regarding efficacy. However, PAGPROS may show signifi-
cant efficacy to one drug but no efficacy to the other. Des-
pite a lack of an evidence base, many formulary regulatory
authorities worldwide typically favour one drug for sub-
sidy over the other [4]. This hinders interchange wherever
the favoured drug is either ineffective or not tolerated [4].
The nature of PAGPROS’s design will directly assess the
utility of cross-over between PGB and GBP and will there-
fore enable formulary regulatory authorities to make more
informed therapeutic decisions than currently.
Recruitment commenced in early 2016, with data col-
lection to be completed by mid 2018. The allocation
concealment and double-blind design minimise bias, and
data collection processes ensure data quality and integ-
rity. The trial team has extensive experience in the de-
sign, conduct and reporting of clinical trials. Results of
the study will be disseminated via publications and
presentations.
Potential weaknesses of PAGPROS
Treatment duration
PAGPROS permits a 4-week titration period, after which
the maximum tolerated dose for each participant will
then be maintained for 4 weeks. The duration of individ-
ual drug study is therefore 8 weeks. In some rare cases,
this might be considered insufficient to test efficacy at
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the optimum dose [10]. Furthermore, because anec-
dotally some patients develop tolerance to SEs incurred
with either PGB or GBP, the study period may also be
too short to detect SE tolerance.
Dosages
Given the restricted doses and study time available in
PAGPROS, it is not possible to introduce either drug in
‘low and slow’ fashion [4]. Because the latter potentially
off-sets the development of SEs [4], PAGPROS may
therefore potentially over-estimate SEs with either drug.
However, at least with GBP, there exists some control in
that a prospective cohort study found SEs in 53% of
patients with CS [10].
Maintenance of background therapies including prior
analgesia
This may affect both efficacy and SE development, poten-
tially increasing both. However, note that this practice is
entirely consistent with NICE-UK guidelines [6, 10], and,
indeed, standard clinical practice. NICE-UK guidelines
state that, when super-adding second-line analgesic agents
(such as GBP and PGB), ‘overlap with first-line agents is
encouraged to avoid decreased pain-control’ [6]. To our
knowledge, only one prospective cohort study has
reflected this practice using GBP in CS [10].
Trial status
Screening for patients for this trial began on 7 March
2016. The first patient was included on 4 April 2016. To
date, 18 participants have successfully completed the
trial, and inclusion is expected to run until 31 June
2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 131 kb)
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